AMGN vs GENB: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AMGN and GENB share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AMGN and GENB exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Amgen (AMGN) is one of the world's largest biotechnology companies, developing, manufacturing, and selling human therapeutics primarily for serious illnesses. Its portfolio spans inflammation, oncology, cardiovascular disease, bone health, and rare diseases, with well-known products that have included Enbrel, Prolia and Xgeva, Repatha, Otezla, and a growing pipeline. Amgen pioneered large-scale recombinant-protein and antibody manufacturing and is a leader in biosimilars as older biologics lose patent protection. The 2023 acquisition of Horizon Therapeutics added rare-disease drugs such as Tepezza and Krystexxa. Amgen is also developing obesity and metabolic candidates, including investigational drugs in the GLP-1 class of weight-loss therapies. Headquartered in Thousand Oaks, California, and founded in 1980, Amgen is a member of the Dow Jones Industrial Average and returns substantial cash to shareholders through a growing dividend and buybacks.

Full AMGN guide

Generate Biomedicines, Inc. builds machine-learning models that design proteins from scratch and then runs the resulting molecules through conventional drug development. The lead program, GB-0895, is a long-acting anti-TSLP antibody for severe asthma engineered for roughly twice-yearly dosing, and it entered global Phase 3 studies (SOLAIRIA-1 and SOLAIRIA-2, about 1,600 patients) after a Phase 1 showed an approximately 89-day half-life. Behind it sit GB-4362, an antibody that mops up circulating MMAE payload to blunt the toxicity of antibody-drug conjugates, which carries FDA Fast Track designation, and GB-5267, a MUC16-directed CAR-T for ovarian cancer being run with Roswell Park. The platform also earns money directly: multi-program collaborations with Amgen and Novartis have paid roughly $110M to date and carry biobucks of up to about $2.9B in combined milestones.

Full GENB guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AMGN drivers: Rare disease and Horizon assets; Obesity and metabolic pipeline.
• GENB drivers: GB-0895 and the six-month dosing pitch; Partner economics as validation and as cash.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Amgen faces patent cliffs as older blockbusters lose exclusivity, exposing them to biosimilar competition and pricing pressure. For GENB, binary clinical risk dominates everything else here: a Phase 3 miss on GB-0895, or a safety signal, would remove most of the value the market is currently assigning.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AMGN if you believe its drivers more; GENB if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AMGN and GENB guides.

AMGN. Amgen trades at a moderate multiple typical of a mature large-cap biopharma, reflecting steady cash flow and a meaningful dividend balanced against patent-cliff and drug-pricing risk. The valuation embeds expectations for the rare-disease and obesity pipelines to offset declines in older franchises. All figures are approximate and move with the share price and reported results; verify current numbers before relying on them.

GENB. No conventional valuation multiple works on a company whose only revenue is partner payments. Stripping out cash leaves an enterprise value near $1.8B for a platform, a Phase 3 antibody and two Phase 1 assets, which prices in a reasonable probability of GB-0895 reaching the market. Quarter-to-quarter revenue moves reflect collaboration milestones landing or not landing, so reading them as a growth trend tends to mislead.

Headline figures (approximate, early 2026): AMGN shows revenue (ttm) ~$33-35 billion (approximate, verify), operating margin ~30%+ (approximate, verify), p/e (ttm) ~20-25x (GAAP varies; approximate, verify), dividend yield ~3% (approximate, verify); GENB shows revenue (ttm) ~$26.5M, all collaboration revenue from Amgen and Novartis, net loss (ttm) ~$269M; ~$67.3M in Q2 2026 alone, cash and marketable securities ~$457M at June 30, 2026, guided to fund operations into H1 2028, market cap ~$2.3B on ~128M shares.

AMGN and GENB are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AMGN and GENB exposure against your real portfolio. It is not an investment adviser.